Acumen Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ABOS | ACIU | ALEC | VYGR | KRSA | ACAD | |
|---|---|---|---|---|---|---|
| Market cap | 15.64M | 227.69M | 254.58M | 115.23M | 1.39B | 3.70B |
| P/E (TTM) | — | — | — | — | — | 9.6 |
| Forward P/E | -0.4 | 3.8 | -3.1 | -1.5 | -8.6 | 23.3 |
| Price/book | 0.5 | 4.3 | -25.6 | 0.7 | -3.9 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −88.47% | −33.62% | +75.38% | −57.14% | +160.90% | −7.88% |
| Today | −7.72% | +9.57% | +11.22% | +2.19% | −4.38% | +4.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ABOS news ›Aquestive Therapeutics GAAP EPS of -$0.18 misses by $0.06, revenue of $7.5M misses by $3.52M
Aquestive Therapeutics Q3 earnings missed on EPS and revenue as losses widened. - Aquestive Therapeutics press release (AQST): Q3 GAAP EPS of -$0.18 misses by $0.06. - Revenue of $7.5M (-41.5% Y/Y) misses by $3.52M.
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Tina Ventura - Chief Investor Relations OfficerWilliam Sibold - CEO, President & DirectorDavid Soergel - Executive VP & Chief Medical OfficerMardi…
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
Arrowhead Pharmaceuticals, Inc.
Aarti Drugs Limited announces Q2, H1 FY27 results
03 Nov 2026, 10:59 PM IST Equity Bulls Stock Report Aarti Drugs Limited INE767A01016 Consolidated Financial Highlights – Q2 FY27 Looking ahead, we are building Aarti Drugs into a more integrated, more diversified and more globally relevant…
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter…
Acumen Pharma tanks as it drops Alzheimer’s candidate - The Pharma Letter
Acumen Pharma tanks as it drops Alzheimer’s candidate The Pharma Letter
Acumen Pharmaceuticals: Altitude-AD Failure Destroys The Investment Thesis (Rating Downgrade)
Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ABOS stock is downgraded to a sell. - Acumen Pharmaceuticals is downgraded to sell after its lead Alzheimer's drug,…
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at…
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of ...
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at…
Acumen Pharmaceuticals’ Earnings Call Pivots on ALTITUDE-AD
Acumen Pharmaceuticals, Inc. ((ABOS)) has held its Q3 earnings call. Read on for the main highlights of the call. Acumen framed the upcoming Phase II ALTITUDE-AD readout of sabirnetug as a central value inflection point, with top-line data…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com16
- seekingalpha.com15
- theglobeandmail.com4
- biospace.com3
- markets.businessinsider.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 61 articles, not a forecast.